Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Ulrike Philipp"'
Autor:
Julia C. Kuehn, Patrick Metzger, Nicolas Neidert, Uta Matysiak, Linda Gräßel, Ulrike Philipp, Sabine Bleul, Thomas Pauli, Julia Falkenstein, Henriette Bertemes, Stepan Cysar, Maria Elena Hess, Anna Verena Frey, Jesús Duque-Afonso, Elisabeth Schorb, Marcia Machein, Jürgen Beck, Oliver Schnell, Nikolas von Bubnoff, Anna L. Illert, Christoph Peters, Tilman Brummer, Marco Prinz, Cornelius Miething, Heiko Becker, Silke Lassmann, Martin Werner, Melanie Börries, Justus Duyster, Dieter H. Heiland, Roman Sankowski, Florian Scherer
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-11 (2024)
Abstract Despite major advances in molecular profiling and classification of primary brain tumors, personalized treatment remains limited for most patients. Here, we explored the feasibility of individual molecular profiling and the efficacy of bioma
Externí odkaz:
https://doaj.org/article/1dc07143d8964d58a48d87e8eab4e848
Autor:
Silvia Waldeck, Jan Mitschke, Sebastian Wiesemann, Michael Rassner, Geoffroy Andrieux, Max Deuter, Jurik Mutter, Anne‐Marie Lüchtenborg, Daniel Kottmann, Laurin Titze, Christoph Zeisel, Martina Jolic, Ulrike Philipp, Silke Lassmann, Peter Bronsert, Christine Greil, Justyna Rawluk, Heiko Becker, Lisa Isbell, Alexandra Müller, Soroush Doostkam, Bernward Passlick, Melanie Börries, Justus Duyster, Julius Wehrle, Florian Scherer, Nikolas von Bubnoff
Publikováno v:
Molecular Oncology, Vol 16, Iss 2, Pp 527-537 (2022)
Circulating tumor DNA (ctDNA) has demonstrated great potential as a noninvasive biomarker to assess minimal residual disease (MRD) and profile tumor genotypes in patients with non‐small‐cell lung cancer (NSCLC). However, little is known about its
Externí odkaz:
https://doaj.org/article/4399d10b1bd049f3a353a6cfadf469f6
Autor:
Michael Rassner, Silvia Waldeck, Marie Follo, Stefanie Jilg, Ulrike Philipp, Martina Jolic, Julius Wehrle, Philipp J. Jost, Christian Peschel, Anna Lena Illert, Justus Duyster, Florian Scherer, Nikolas von Bubnoff
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 6, p 5411 (2023)
Background: Mutations in cKIT or PDGFRA are found in up to 90% of patients with gastrointestinal stromal tumors (GISTs). Previously, we described the design, validation, and clinical performance of a digital droplet (dd)PCR assay panel for the detect
Externí odkaz:
https://doaj.org/article/6eb23afb46f54cd498e8f7c54f9d2070
Autor:
Saskia Hussung, Dilara Akhoundova, Julian Hipp, Marie Follo, Rhena F. U. Klar, Ulrike Philipp, Florian Scherer, Nikolas von Bubnoff, Justus Duyster, Melanie Boerries, Uwe Wittel, Ralph M. Fritsch
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Novel biomarkers and molecular monitoring tools hold potential to improve outcome for patients following resection of pancreatic ductal adenocarcinoma (PDAC). We hypothesized that the combined longitudinal analysis of mutated cell
Externí odkaz:
https://doaj.org/article/df151022f76648449f2bf707053b3b13
Autor:
Julius Wehrle, Ulrike Philipp, Martina Jolic, Marie Follo, Saskia Hussung, Silvia Waldeck, Max Deuter, Michael Rassner, Jan Braune, Justyna Rawluk, Christine Greil, Cornelius F. Waller, Heiko Becker, Jesús Duque-Afonso, Anna L. Illert, Ralph M. Fritsch, Frank Meiss, Justus Duyster, Nikolas von Bubnoff, Florian Scherer
Publikováno v:
Diagnostics, Vol 10, Iss 8, p 550 (2020)
Background: Circulating tumor DNA (ctDNA) in the blood plasma of cancer patients is an emerging biomarker used across oncology, facilitating noninvasive disease monitoring and genetic profiling at various disease milestones. Digital droplet PCR (ddPC
Externí odkaz:
https://doaj.org/article/e63030888c5d4ece9ce2c4dc54ca2dd8
Autor:
Justyna Rawluk, Anne-Marie Lüchtenborg, Peter Bronsert, Julius Wehrle, Nikolas von Bubnoff, Martina Jolic, Alexandra Müller, Jan Mitschke, Silvia Waldeck, Melanie Börries, Justus Duyster, Soroush Doostkam, Laurin Titze, Heiko Becker, Christoph Zeisel, Sebastian Wiesemann, Silke Lassmann, Max Deuter, Daniel Kottmann, Florian Scherer, Jurik Mutter, Ulrike Philipp, Bernward Passlick, Lisa K. Isbell, Geoffroy Andrieux, Michael Rassner, Christine Greil
Publikováno v:
Molecular Oncology, Vol 16, Iss 2, Pp 527-537 (2022)
Molecular Oncology
Molecular Oncology
Circulating tumor DNA (ctDNA) has demonstrated great potential as a noninvasive biomarker to assess minimal residual disease (MRD) and profile tumor genotypes in patients with non‐small‐cell lung cancer (NSCLC). However, little is known about its
Autor:
Dagmar von Bubnoff, Marie Follo, Florian Schiller, Jan Braune, Ulrike Philipp, Julius Wehrle, Frank Meiss, Michael Mix, Saskia Hussung, Erika Graf, Ralph Fritsch, Justus Duyster, David Rafei-Shamsabadi, Dietmar Pfeifer, Nikolas von Bubnoff, Laura Keller
Publikováno v:
JCO Precision Oncology. :20-31
PURPOSE We evaluated circulating tumor DNA (ctDNA) for detecting tumor burden in melanoma and examined whether early changes in the number of ctDNA copies predict response to treatment. PATIENTS AND METHODS We included 12 patients with stage III and
Autor:
Silvia Waldeck, Philipp J. Jost, Victoria Kehl, Christian Peschel, Stefanie Jilg, Peter Hohenberger, Ulrike Philipp, Jacqueline Maier, Sebastian Bauer, Nikolas von Bubnoff, Justus Duyster, Timo Gaiser, Jan Mitschke, Thoralf Lange, Andreas Sauter, Marie Follo, Katja Specht, Michael Rassner
Publikováno v:
International Journal of Cancer. 145:2292-2303
This prospective trial aimed to investigate whether tumor-specific cKIT and PDGFRA mutations can be detected and quantified in circulating tumor (ct)DNA in patients with active GIST, and whether detection indicates disease activity. We included 25 pa
Autor:
Melanie Boerries, Dilara Akhoundova, Rhena F. U. Klar, Ralph Fritsch, Nikolas von Bubnoff, Saskia Hussung, Ulrike Philipp, Julian Hipp, Marie Follo, Justus Duyster, Florian Scherer, Uwe A. Wittel
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Cancer
BMC Cancer
Background Novel biomarkers and molecular monitoring tools hold potential to improve outcome for patients following resection of pancreatic ductal adenocarcinoma (PDAC). We hypothesized that the combined longitudinal analysis of mutated cell-free pla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33ca7ff86ed7bcbef9267c23e2331c75
https://doi.org/10.5167/uzh-198678
https://doi.org/10.5167/uzh-198678
Autor:
Saskia Hussung, Dilara Akhoundova, Julian Hipp, Marie Follo, Rhena Klar, Ulrike Philipp, Florian Scherer, Nikolas von Bubnoff, Justus Duyster, Melanie Börries, Uwe Wittel, Ralph Fritsch
Background: Novel biomarkers and molecular monitoring tools hold potential to improve outcome for patients following resection of pancreatic ductal adenocarcinoma (PDAC). We hypothesized that the combined longitudinal analysis of mutated cell-free pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a9234bac5f976d0799c8f471eb3975a
https://doi.org/10.21203/rs.3.rs-60848/v2
https://doi.org/10.21203/rs.3.rs-60848/v2